BACKGROUND: In an attempt to avoid unknown influence, most neuroimaging studies examining the pathophysiology of posttraumatic stress disorder (PTSD) exclude patients taking medications. Here we review the empirical evidence for relevant medications having a confounding effect on task performance or cerebral blood flow (CBF) in this population. The evidence for potentially confounding effects of psychotherapy in PTSD are also discussed. METHODS: The literature that we reviewed was obtained through a PubMed search from 1980 to 2009 using the search terms posttraumatic stress disorder, PTSD, psychotropic medications, neuroimaging, functional magnetic resonance imaging, positron emission tomography, cerebral blood flow, CBF, serotonin-specific reuptake blocker, benzodiazepine, ketamine, methamphetamine, lamotrigine and atypical antipsychotic agents. RESULTS: The empirical evidence for relevant medications having a confounding effect on task performance or CBF in relevant areas remains sparse for most psychotropic medications among patients with PTSD. However, considerable evidence is accumulating for 2 of the most commonly prescribed medication classes (serotonin-specific reuptake inhibitors and benzodiazepines) in healthy controls. Compelling data for the potentially confounding effects on brain areas relevant to PTSD for psychotherapeutic interventions are also accumulating. CONCLUSION: Neuroimaging studies examining the pathophysiology of PTSD should ideally recruit both medicated (assuming that the medication treatment has not resulted in the remission of symptoms) and unmedicated participants, to allow the findings to be generalized with greater confidence to the entire population of patients with PTSD. More research is needed into the independent effects of medications on task performance and CBF in regions of interest in PTSD. Neuroimaging studies should also take into account whether patients are currently engaged in psychotherapeutic treatment.
BACKGROUND: In an attempt to avoid unknown influence, most neuroimaging studies examining the pathophysiology of posttraumatic stress disorder (PTSD) exclude patients taking medications. Here we review the empirical evidence for relevant medications having a confounding effect on task performance or cerebral blood flow (CBF) in this population. The evidence for potentially confounding effects of psychotherapy in PTSD are also discussed. METHODS: The literature that we reviewed was obtained through a PubMed search from 1980 to 2009 using the search terms posttraumatic stress disorder, PTSD, psychotropic medications, neuroimaging, functional magnetic resonance imaging, positron emission tomography, cerebral blood flow, CBF, serotonin-specific reuptake blocker, benzodiazepine, ketamine, methamphetamine, lamotrigine and atypical antipsychotic agents. RESULTS: The empirical evidence for relevant medications having a confounding effect on task performance or CBF in relevant areas remains sparse for most psychotropic medications among patients with PTSD. However, considerable evidence is accumulating for 2 of the most commonly prescribed medication classes (serotonin-specific reuptake inhibitors and benzodiazepines) in healthy controls. Compelling data for the potentially confounding effects on brain areas relevant to PTSD for psychotherapeutic interventions are also accumulating. CONCLUSION: Neuroimaging studies examining the pathophysiology of PTSD should ideally recruit both medicated (assuming that the medication treatment has not resulted in the remission of symptoms) and unmedicated participants, to allow the findings to be generalized with greater confidence to the entire population of patients with PTSD. More research is needed into the independent effects of medications on task performance and CBF in regions of interest in PTSD. Neuroimaging studies should also take into account whether patients are currently engaged in psychotherapeutic treatment.
Authors: Hilary P Blumberg; Nelson H Donegan; Charles A Sanislow; Susan Collins; Cheryl Lacadie; Pawel Skudlarski; Ralitza Gueorguieva; Robert K Fulbright; Thomas H McGlashan; John C Gore; John H Krystal Journal: Psychopharmacology (Berl) Date: 2005-10-26 Impact factor: 4.530
Authors: Marc J Kaufman; Michael E Henry; Blaise deB Frederick; John Hennen; Rosemond A Villafuerte; Eve P Stoddard; Mark E Schmidt; Bruce M Cohen; Perry F Renshaw Journal: Biol Psychiatry Date: 2003-09-01 Impact factor: 13.382
Authors: Benedicto Crespo-Facorro; Roberto Roiz-Santiáñez; Rocío Pérez-Iglesias; José M Pelayo-Terán; José M Rodríguez-Sánchez; Diana Tordesillas-Gutiérrez; MariLuz Ramírez; Obdulia Martínez; Agustin Gutiérrez; Enrique Marco de Lucas; José L Vázquez-Barquero Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2008-10-07 Impact factor: 5.067
Authors: Marco A M Peluso; David C Glahn; Koji Matsuo; E Serap Monkul; Pablo Najt; Frank Zamarripa; Jinqi Li; Jack L Lancaster; Peter T Fox; Jia-Hong Gao; Jair C Soares Journal: Psychiatry Res Date: 2009-06-28 Impact factor: 3.222
Authors: Vanessa M Brown; Kevin S LaBar; Courtney C Haswell; Andrea L Gold; Gregory McCarthy; Rajendra A Morey Journal: Neuropsychopharmacology Date: 2013-08-09 Impact factor: 7.853
Authors: Jared A Rowland; Jennifer R Stapleton-Kotloski; Greg E Alberto; Justin A Rawley; Robert J Kotloski; Katherine H Taber; Dwayne W Godwin Journal: Brain Connect Date: 2017-01-24
Authors: Kathleen Thomaes; Ethy Dorrepaal; Nel Draijer; Michiel B de Ruiter; Bernet M Elzinga; Zsuzsika Sjoerds; Anton J van Balkom; Johannes H Smit; Dick J Veltman Journal: Soc Cogn Affect Neurosci Date: 2011-12-07 Impact factor: 3.436
Authors: Moji Aghajani; Ilya M Veer; Marie-José van Hoof; Serge A R B Rombouts; Nic J van der Wee; Robert R J M Vermeiren Journal: Hum Brain Mapp Date: 2016-01-06 Impact factor: 5.038
Authors: Daniela Rabellino; Maria Densmore; Jean Théberge; Margaret C McKinnon; Ruth A Lanius Journal: Hum Brain Mapp Date: 2018-04-17 Impact factor: 5.038
Authors: Noah S Philip; Yuliya I Kuras; Thomas R Valentine; Lawrence H Sweet; Audrey R Tyrka; Lawrence H Price; Linda L Carpenter Journal: Psychiatry Res Date: 2013-10-03 Impact factor: 3.222
Authors: Rajendra A Morey; Andrea L Gold; Kevin S LaBar; Shannon K Beall; Vanessa M Brown; Courtney C Haswell; Jessica D Nasser; H Ryan Wagner; Gregory McCarthy Journal: Arch Gen Psychiatry Date: 2012-11